Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Lavezzi SM, de Jong J, Neyens M, Cramer P, Demirkan F, Fraser G, Bartlett N, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Goy A, Ganguly S, Salman M, Howes A, Mahler M, De Nicolao G, Poggesi I. Lavezzi SM, et al. Among authors: de nicolao g, de jong j. Pharm Res. 2019 May 1;36(7):93. doi: 10.1007/s11095-019-2605-8. Pharm Res. 2019. PMID: 31044267 Clinical Trial.
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I. Marostica E, et al. Among authors: de trixhe xw, de nicolao g, de jong j. Cancer Chemother Pharmacol. 2015 Jan;75(1):111-21. doi: 10.1007/s00280-014-2617-3. Epub 2014 Nov 8. Cancer Chemother Pharmacol. 2015. PMID: 25381051 Clinical Trial.
Current mathematical models for cancer drug discovery.
Carrara L, Lavezzi SM, Borella E, De Nicolao G, Magni P, Poggesi I. Carrara L, et al. Among authors: de nicolao g. Expert Opin Drug Discov. 2017 Aug;12(8):785-799. doi: 10.1080/17460441.2017.1340271. Epub 2017 Jun 22. Expert Opin Drug Discov. 2017. PMID: 28595492 Review.
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
Rocchetti M, Germani M, Del Bene F, Poggesi I, Magni P, Pesenti E, De Nicolao G. Rocchetti M, et al. Among authors: de nicolao g. Cancer Chemother Pharmacol. 2013 May;71(5):1147-57. doi: 10.1007/s00280-013-2107-z. Epub 2013 Feb 21. Cancer Chemother Pharmacol. 2013. PMID: 23430120
82 results